Scarica l'app Stockscreener
11.68
3.36%
0.38
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$11.30
Aprire:
$10.81
Volume 24 ore:
1.13M
Relative Volume:
2.18
Capitalizzazione di mercato:
$618.65M
Reddito:
$8.78M
Utile/perdita netta:
$-104.70M
Rapporto P/E:
-4.6166
EPS:
-2.53
Flusso di cassa netto:
$-82.68M
1 W Prestazione:
-3.15%
1M Prestazione:
+3.27%
6M Prestazione:
-20.87%
1 anno Prestazione:
+140.08%
Intervallo 1D:
$10.81
$11.84
Intervallo di 1 settimana:
$10.61
$12.58
Portata 52W:
$4.09
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Confronta STOK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
11.68 | 618.65M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Chardan Capital Initiates Coverage of Stoke Therapeutics (STOK) with Buy Recommendation - MSN
Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownHere's What Happened - MarketBeat
Chardan Capital Initiates Coverage on Stoke Therapeutics (NASDAQ:STOK) - MarketBeat
Jane Street Group LLC Acquires 255,028 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
(STOK) Proactive Strategies - Stock Traders Daily
Stoke Therapeutics (NASDAQ:STOK) Trading Down 5%What's Next? - MarketBeat
Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth - Yahoo Finance
Charles Schwab Investment Management Inc. Boosts Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics (NASDAQ:STOK) pulls back 9.1% this week, but still delivers shareholders solid 136% return over 1 year - Simply Wall St
Fmr LLC Lowers Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics’ (STOK) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $20.83 Average Target Price from Analysts - MarketBeat
Stoke therapeutics' general counsel sells $185,978 in stock - Investing.com
Stoke Therapeutics chief medical officer sells $33,595 in stock By Investing.com - Investing.com UK
Stoke therapeutics CEO Edward Kaye sells $78,837 in stock By Investing.com - Investing.com South Africa
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Bought by BNP Paribas Financial Markets - MarketBeat
Stoke Therapeutics chief medical officer sells $33,595 in stock - Investing.com
Stoke Therapeutics chief medical officer Ticho sells $178,182 in stock By Investing.com - Investing.com Canada
Stoke therapeutics CEO Edward Kaye sells $78,837 in stock - Investing.com India
Stoke Therapeutics chief medical officer Ticho sells $178,182 in stock - Investing.com
Stoke therapeutics' general counsel sells $123,890 in stock - Investing.com
Stoke therapeutics' general counsel sells $123,890 in stock By Investing.com - Investing.com UK
(STOK) Investment Report - Stock Traders Daily
Stoke Therapeutics Gains FDA Breakthrough for Epilepsy Drug - MSN
Intech Investment Management LLC Invests $160,000 in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study - GuruFocus.com
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome - newsbreak.com
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug - MSN
Stoke Therapeutics' Dravet Drug Shows Remarkable 87% Seizure Reduction in Clinical Data - StockTitan
Stoke Therapeutics, Inc. (NASDAQ:STOK) Stake Lifted by RTW Investments LP - MarketBeat
U.S. STOCKS Stoke Therapeutics, Foot Locker, Marvell - XM
Pure Storage Posts Upbeat Results, Joins Cross Country… - Inkl
Stoke Therapeutics' drug 'zorevunersen' earns FDA breakthrough tag; shares leap - Investing.com Nigeria
Stoke Therapeutics Shares Rise Premarket on Key FDA Designation - MarketWatch
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome - Business Wire
Stoke Therapeutics' drug 'zorevunersen' earns FDA breakthrough tag; shares leap By Investing.com - Investing.com South Africa
Stoke Therapeutics CMO sells $120,698 in stock By Investing.com - Investing.com Canada
Stoke Therapeutics CMO sells $120,698 in stock - Investing.com India
Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting - Business Wire
Stoke Therapeutics: First Disease Modifying Therapy For Dravet, Still In Need Of Regulatory Clarity (NASDAQ:STOK) - Seeking Alpha
An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond - PharmaVoice
Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $20.83 Average PT from Analysts - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of “Buy” by Brokerages - Defense World
How To Trade (STOK) - Stock Traders Daily
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 8.3%What's Next? - MarketBeat
Redmile Group, LLC Adjusts Stake in Stoke Therapeutics Inc - GuruFocus.com
Los Angeles Capital Management LLC Grows Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Stoke Therapeutics Inc Azioni (STOK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Dec 09 '24 |
Sale |
13.61 |
13,666 |
185,978 |
21,476 |
| Kaye Edward M. MD | CEO |
Dec 09 '24 |
Sale |
12.99 |
6,786 |
88,158 |
61,885 |
| Ticho Barry | CHIEF MEDICAL OFFICER |
Dec 06 '24 |
Sale |
12.78 |
13,945 |
178,182 |
47,332 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Dec 06 '24 |
Sale |
12.78 |
9,696 |
123,891 |
35,142 |
| Kaye Edward M. MD | CEO |
Dec 06 '24 |
Sale |
12.78 |
6,170 |
78,837 |
68,671 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):